A simple high-performance liquid chromatography assay for the major cisapride metabolite, norcisapride, in human urine

被引:2
作者
Addison, RS [1 ]
Duffy, SL [1 ]
Mathers, SR [1 ]
机构
[1] Univ Queensland, Royal Brisbane Hosp, Dept Med, Ctr Studies Drug Disposit, Brisbane, Qld 4029, Australia
关键词
D O I
10.1093/chromsci/37.3.61
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A simple high-performance liquid chromatography assay using fluorescence detection for the major metabolite of the gastric prokinetic drug cisapride, norcisapride, is presented. Analysis is performed using an Alltech Platinum EPS C8 column with a mobile phase made up of methanol and 0.02M sodium dihygrogen phosphate (45:55, v/v) containing triethylamine (1 g/L). Complete resolution is achieved among norcisapride, the internal standard (metoclopramide), and endogenous urinary components. The assay is linear over the range 50-2000 ng/m with a mean recovery of 71.2% across the analytical range following solvent extraction with toluene-isoamyl alcohol (95:5, v/v). Intraday coefficients of variation (precision) determined at 200 and 1000 ng/m are 6.0 and 9.8%, respectively, and interday coefficients of variation are 8.8 and 6.6%, respectively. Intra- and interassay accuracy (as mean relative error) determined at the same concentrations is within 10% in all cases. An analysis of urine samples from a healthy volunteer following the administration of a single 10-mg oral dose of cisapride is shown.
引用
收藏
页码:61 / 64
页数:4
相关论文
共 7 条
[1]   PHARMACOKINETICS AND PHARMACODYNAMICS OF CISAPRIDE IN PATIENTS UNDERGOING HEMODIALYSIS [J].
GLADZIWA, U ;
BARES, R ;
KLOTZ, U ;
DAKSHINAMURTY, KV ;
ITTEL, TH ;
SEILER, KU ;
SIEBERTH, HG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (06) :673-681
[2]   CISAPRIDE - A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE AS A PROKINETIC AGENT IN GASTROINTESTINAL MOTILITY DISORDERS [J].
MCCALLUM, RW ;
PRAKASH, C ;
CAMPOLIRICHARDS, DM ;
GOA, KL .
DRUGS, 1988, 36 (06) :652-681
[3]  
MEULDERMANS W, 1988, DRUG METAB DISPOS, V16, P403
[4]  
MEULDERMANS W, 1988, DRUG METAB DISPOS, V16, P410
[5]   ANALYSIS OF CISAPRIDE IN NEONATAL PLASMA USING HIGHPERFORMANCE LIQUID-CHROMATOGRAPHY WITH A BASE-STABLE COLUMN AND FLUORESCENCE DETECTION [J].
PREECHAGOON, Y ;
CHARLES, BG .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 670 (01) :139-143
[6]   A RISK-BENEFIT ASSESSMENT OF CISAPRIDE IN THE TREATMENT OF GASTROINTESTINAL DISORDERS [J].
TACK, J ;
COREMANS, G ;
JANSSENS, J .
DRUG SAFETY, 1995, 12 (06) :384-392
[7]   CISAPRIDE - AN UPDATED REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC EFFICACY AS A PROKINETIC AGENT IN GASTROINTESTINAL MOTILITY DISORDERS [J].
WISEMAN, LR ;
FAULDS, D .
DRUGS, 1994, 47 (01) :116-152